Key facts
- General Proximity’s last known valuation is $2.1M (Jan 2020).
- It has raised $16.1M; the latest was Later Stage VC ($16.0M) in Dec 2024.
- Notable investors include Y Combinator, Mana Ventures, Bossa Invest, Felicis, Jeff Dean — 26 tracked in total.
- 1 investment vehicle was formed to buy General Proximity shares in the last 12 months, reporting $276K sold to 14 investors, per SEC Form D filings.
- Status: Privately Held (backing).
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for General Proximity
- ·The full record, as it builds
Funding rounds
No funding rounds for General Proximity are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Secondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy General Proximity shares, reporting $276K sold to 14 investors. Most recent filing Apr 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About General Proximity
Operator of a biotech company intended to develop drugs that activate existing cellular machinery. The company produces the next generation of induced-proximity medicines, enabling doctors to treat harmful human diseases.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2019
- Employees
- 21
- Website
- generalproximity.bio/
- Ownership
- Privately Held (backing)
General Proximity doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in General Proximity shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on General Proximity in its N-PORT filings yet. We sweep new filings monthly.